Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
gap at .04
https://www.bloomberg.com/quote/AEPP:US
it's what's listed as the company's number here.
i don't know what nigel said or didn't say, but that is indeed his number.
deal pushed back...
i'm just posting what's in the filings.
OTC Markets lists a verified as of March 1
Share Structure
Market Value1 $1,960,666 a/o Mar 20, 2017
Authorized Shares 500,000,000 a/o Mar 01, 2017
Outstanding Shares 33,231,633 a/o Mar 01, 2017
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 28,311,633 a/o Jan 13, 2017
Par Value Not Available
If you look in the filings from March 8
https://www.sec.gov/Archives/edgar/data/1419936/000138038917000014/aepp_schedule14f1.htm
I emailed him a while ago. If he replies I'll be sure to let the board know.
What we know based on the filing two weeks ago:
1. Kistler took over the company in January.
2. Kistler converted debt owed to him into 60M common shares.
3. Kistler "plans" on selling those shares plus a few more to Redman.
4. AEPP went to Pink status in early March, probably the same time Kistler converted those shares.
and now VERT is on the ask. what a day here
the only reason people think this merger is off is based on a lie.
wrong, they were PC when they put out the 14f-1 that got this party started in the first place.
they likely went pink as part of the deal since it would cost a forture and take an eternity for oncolix to get their books in good enough order for public reporting.
next wave of selling was induced by the removal of redman from the otc markets page.
again, i'd like to point out that payne was also removed but then added back...
otc markets page has been changed twice.
they removed redman and payne today, but then went back and added payne.
http://www.otcmarkets.com/stock/AEPP/profile
redman stopped wanting calls on this, but they left payne in there as a clue...
no "reading between the lines". lol
kistler converted the debts owed to him into 60M shares of stock earlier this month. within days he had the purchase agreement in place. he wouldn't have done that if he didn't want to make the deal unless you think that 8k is just a cover he can use to drive up prices and dump stock.
but again, why wouldn't oncolix shut this rumor or deal down if kistler was blatantly scamming? they would unless now redman and payne are in on it.
ok folks, here's your chance to get out if you want it.
if the deal was dead he would have told us that.
waiting for the 8k to show oncolix is taking over aepp has been stated in the documents filed with the SEC that will happen.
i can wait an extra few days if i need to to make a fortune.
relax. it could be a few days. or not.
On March 6, 2017, the Board's appointed Michael T. Redman as a director to our Board and as our Chief Executive Officer, President, Principal Executive Officer and Principal Financial Officer. Mr. Redman created and named Oncolix from technology acquired from the Greenville Hospital System, the current majority shareholder of Oncolix. Since joining Oncolix, Mr. Redman, on behalf of the Company, has prepared business plans, presented at major life science conferences and has been primarily responsible for the Company having had issued eight US patents and additional foreign patents. Under Mr. Redman's guidance, the Company has raised more than $15 million in financing, licensed a proprietary expression system required to manufacture the Company's lead drug, solved manufacturing challenges, hired key personnel and took one oncology drug from research stage through Phase II (melanoma) and a second drug from the preclinical development to Phase I clinical trials (ovarian cancer), and successfully obtained orphan designation from the FDA for such drug. Mr. Redman has extensive contacts in the investment community, both domestically and internationally, large pharmaceutical companies, contract research organizations (both domestically and internationally) and research institutions for sponsored research (including MD Anderson Cancer Center). Prior to forming Oncolix, Mr. Redman was the CEO of Bone Medical in Australia and the CEO and co-founder of Opexa Pharmaceuticals, which commenced operations in February of 2001 and was sold to PharmaFrontiers Corporation in November 2004. Mr. Redman also acts as an interim CEO to Onco CNS, a small private start up that he advises on his own time. In addition to the above CEO positions, Mr. Redman also has held key management positions with Zonagen, Aronex Pharmaceuticals, Biovail, and American Home Products. Mr. Redman is an active member of the Licensing Executives Society and formerly served on its Executive Committee. Mr. Redman earned a BA in Biology from the University of Missouri and a Master's in Business Administration from the University of Phoenix.
http://insiders.morningstar.com/trading/executive-profile.action?PersonId=PS0000AMYY&flag=Executive&t=PINX:AEPP®ion=usa&culture=en-US&cur=
what stands out to me is that the phase one trials are successfully moving along with positive results. i wasn't even sure if they had started...this is great!
news could drop anytime about a deal completing.
might be after hours, but it might be next week.
oncolix 8 patents
orphan drug status
phase I trials with positive results to date
NASDAQ officers
$15M+ VC funding to date
no doubt. there are very few shares available.
i'm not sure what the argument here is exactly, but if your chart is sending this to $.25, i'm not going to complain...
correct about what?
did your chart read the 8k that was released last week?
if and when 8s are cleared, look out...
you're the moderator here. i nominate you.
yeah.
or short based on what you see on the chart, ignoring the rest of the story here. doesn't matter to me either way. if and when news drops it's over.
i have no idea what its value is. they do have many patents, orphan drug status and have raised over $15M to date. there are phase 1 human clinical trials underway or completed as well.
redman is acquiring 2/3 of those 90M. the rest are the 30Mish figure you're seeing cited.
Donald Payne, the #2 man with Oncolix.
https://vimeo.com/2577241
Mr. Donald Payne, CPA, MBA, serves as a Senior Vice President of Finance & Administration at Oncolix, Inc. Mr. Payne is responsible for financial, accounting, intellectual property administration and general administration of the Oncolix’s activities. Mr. Payne has held various senior management positions at Nanospectra Biosciences, Sensus Drug Development, LifeCell Corporation, Aprogenex and Entex Energy. His financial experience includes initial public offerings on the New York and American Stock Exchanges and numerous private offerings. He serves as the Director of Pressure Biosciences (Nasdaq:PBIO) and Nanospectra Biosciences. He has is a co-author of 9 scientific publications and is a co-inventor of 4 issued or pending patent applications. He holds various advisory positions to academic and economic development entities. Mr. Payne received an MBA from Rice University in 1992 (summa cum laude), a BBA from Texas A&M University in 1976 (summa cum laude) and is a licensed CPA (Texas, 1978).
agree. that's why this is speculation and why you have the chance to get in at such a low price.
i know i'm comforted as an investor when i look at who these two guys are. they aren't scammers that we know of and have great biotech backgrounds. i'd be shocked if they had any intention other than to build this price. they won't raise jack if they kill the price now...common sense here...unless you're dealing with pinky scammers or morons. don't think either of those apply here.
there's little doubt they need funding. cancer trials are expensive.
even if they sell a little stock it won't mean anything to you if it means they're progressing to phase II. if we get news that that's where they are, this still will soar faster than anybody can believe.
the most recent 8k actually says they've raised over $15M...
nobody knows. however, our new management team has a winning track record. they took a bio startup and sold it for $20M three years later and that company is now Opexa Therapeutics on NASDAQ.
they could come in a screw the shareholder, but it seems unlikely they would invest this much into a shell only to dilute the stock to death and soil their own reputations at the same time.
can't tell. https://clinicaltrials.gov/ct2/show/study/NCT02534922
this hasn't been updated since sept.